[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:actionable-variation":3},{"name":4,"total":5,"recruiting":6,"trials":7},"Actionable Variation",1,0,[8],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06246110","A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC",[12],"Phase 2","ACTIVE_NOT_RECRUITING","2026-08-03T03:29:57.653021Z","2026-05-05T02:43:28.886266Z"]